Bone malignancies, particularly high-grade primary bone sarcomas, remain clinically challenging due to early dissemination, marked heterogeneity, and limited progress in systemic therapies for metastatic or relapsed disease. While genomics and transcriptomics have clarified structural complexity and transcriptional programs, they provide only an indirect view of the functional machinery that ultimately drives invasion, immune escape, and therapy resistance. Proteomics and phosphoproteomics offer a complementary and often non-redundant layer by reporting protein abundance, pathway activity states, and actionable targets at the execution level. However, the strength of proteomics evidence is currently uneven across bone malignancy entities, with osteosarcoma providing the most mature cohort-scale multi-omics context, while emerging cohort-scale proteomics is increasingly available for selected entities such as Ewing sarcoma. In this Review, we synthesize recent advances in mass spectrometry–based proteomics for bone malignancies, using osteosarcoma as the primary exemplar where cohort-scale proteomics / phosphoproteomics-integrated studies are most mature, while selectively incorporating evidence from other bone tumors and skeletal metastasis contexts. To address evidence heterogeneity explicitly, we highlight where conclusions are supported by cohort-scale tumor proteomics/proteogenomics versus where evidence remains exploratory, model-driven, or cross-entity extrapolations). We summarize key results from bulk tissue proteomics, circulating proteomics, extracellular vesicle (EV) and secretome profiling, and highlight how these data have revealed recurrent biological axes including extracellular matrix remodeling and cell–matrix signaling, metabolic rewiring and stress-response programs, and immune/stromal contexture. We further discuss how multi-omics integration refines molecular subtyping, links bulk signatures to functional dependencies, and supports biomarker prioritization with translational intent (e.g., secretome-informed circulating candidates). We additionally provide a practical comparison of proteomics workflows (label-free DDA/DIA, isobaric labeling, phosphoproteomics, top-down, and low-input/single-cell methods) and summarize key barriers to clinical implementation (pre-analytics, standardization, QC governance, and assay/regulatory considerations). Finally, we outline emerging single-cell and ultra-low-input proteomics technologies and propose a staged roadmap for their implementation in bone tumor research, emphasizing feasibility atlases, integrated multi-omics cohorts, and translation into targeted assays and clinically deployable risk models. Collectively, available evidence suggests that proteomics may become an increasingly important pillar for precision medicine in bone malignancies by bridging molecular alterations to actionable functional states and cellular mechanisms. Real-world translation will require fit-for-purpose study designs, harmonized SOPs and multicenter benchmarking, and disciplined down-selection of discovery signatures into validated targeted assays that demonstrably add value beyond existing clinical predictors.
Chen et al. (Wed,) studied this question.